Prabhakar Rajan is a member of the urological robotic surgery team, with a specialist interest in the surgical treatment of prostate cancer and advanced germ cell tumours.
Mr. Rajan studied physiology and medicine at Cambridge University, and completed junior surgical and senior urological residencies in Edinburgh and Glasgow, respectively.
After fellowship training in robotic surgery at the Karolinska University Hospital, Stockholm, Sweden, he was appointed as a Consultant in Urology with an interest in upper tract laparoscopy within NHS Greater Glasgow and Clyde, and moved to UCLH and Barts Health NHS Trusts in October 2015.
Mr. Rajan is a Group Leader at Barts Cancer Institute, Queen Mary University of London and Turing Fellow at the Alan Turing Institute, London, UK. He undertook his PhD in prostate cancer biology at Newcastle University, Newcastle-upon-Tyne and post-doctoral research at the CR-UK Beatson Institute, Glasgow. His laboratory research focusses on genetic changes in prostate cancer cells that underlie disease recurrence. His clinical research examines outcomes following robot-assisted radical prostatectomy and explores minimally-invasive surgical interventions for germ cell tumours to reduce chemotherapy side effects.
He is one of only a handful of academic surgeons in the UK to have held a RCSEng/CR-UK Clinician Scientist Fellowship in Surgery.
1. Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles. Lauria A, Peirone S, Giudice MD, Priante F, Rajan P, Caselle M, Oliviero S, Cereda M. Nucleic Acids Res. 2020; 48(4):1730-1747 PMID: 31889184
2. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J; CORE-ARV-CTC and ProBIO Investigators. JAMA Oncol. 2019; 5(7):1060-1062 PMID: 31046065
3. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY. Clin Cancer Res. 2019; 25(6):1766-1773 PMID: 30209161
4. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Oeyen S, van Dam P-J, Van den Eynden G, Rutten A, Aly M, Nordstrom T, Van Laere S, Rantalainen M, Rajan P, Egevad L, Ullen A, Yachnin J, Dirix L, Gronberg H, Lindberg J. Genome Med 2018; 10(1):85 PMID: 30458854
5. The effect of comorbidity on prostate-cancer specific mortality: a prospective observational study. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G, Wiklund NP. J Clin Oncol. 2017; 35(31):3566-3574 PMID: 28930493
6. Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. Rajan P*, Sudbery IM*, M. Eugenia M. Villasevil MEM, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID, Leung HY. Eur Urol. 2013; pii: S0302-2838(13)00832-4 PMID: 24054872 *Equal contributors
7. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. Rajan P*, Gaughan L*, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ. J Pathol. 2008; 215(1):67-77 PMID: 18273831 *Equal contributors